BridgeBio PharmaBBIO
BBIO
About: BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Employees: 730
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
404% more call options, than puts
Call options by funds: $389M | Put options by funds: $77.2M
42% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 36
34% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 77
15% more funds holding in top 10
Funds holding in top 10: 13 [Q3] → 15 (+2) [Q4]
10% more capital invested
Capital invested by funds: $4.4B [Q3] → $4.85B (+$449M) [Q4]
4% more funds holding
Funds holding: 251 [Q3] → 261 (+10) [Q4]
1.56% more ownership
Funds ownership: 91.94% [Q3] → 93.5% (+1.56%) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$49
40%
upside
Avg. target
$59
68%
upside
High target
$95
171%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
JP Morgan Anupam Rama 24% 1-year accuracy 15 / 62 met price target | 42%upside $50 | Overweight Maintained | 24 Mar 2025 |
Citigroup David Lebowitz 32% 1-year accuracy 6 / 19 met price target | 40%upside $49 | Buy Maintained | 21 Feb 2025 |
Cantor Fitzgerald Josh Schimmer 22% 1-year accuracy 12 / 54 met price target | 171%upside $95 | Overweight Reiterated | 21 Feb 2025 |
Scotiabank Greg Harrison 49% 1-year accuracy 19 / 39 met price target | 48%upside $52 | Sector Outperform Maintained | 21 Feb 2025 |
HC Wainwright & Co. Raghuram Selvaraju 33% 1-year accuracy 111 / 332 met price target | 40%upside $49 | Buy Reiterated | 13 Feb 2025 |
Financial journalist opinion
Based on 6 articles about BBIO published over the past 30 days
Positive
Benzinga
3 days ago
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
The Japanese Ministry of Health, Labour and Welfare on Thursday approved BridgeBio Pharma, Inc.‘s BBIO acoramidis, under the brand name Beyonttra, for adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
Neutral
GlobeNewsWire
3 days ago
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM
In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated The approval was based on a Japanese Phase 3 study and the global ATTRibute-CM Phase 3 trial, which demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date. Key data from the ATTRibute-CM study include: In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalization (CVH)) durably separated relative to placebo A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30 A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30 BridgeBio will receive a $30 million milestone payment from Alexion, AstraZeneca Rare Disease, with royalties in the low double digits on net sales of Beyonttra in Japan PALO ALTO, Calif.
Neutral
GlobeNewsWire
6 days ago
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions
PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that cardiovascular outcomes data in patients with variant and wild-type ATTR-CM from the ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a flatboard poster presentation at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo, taking place in Chicago, Illinois on March 29-31, 2025. Additionally, BridgeBio was selected to share five poster presentations and two moderated posters on ATTR-CM.
Neutral
GlobeNewsWire
1 week ago
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that on March 19, 2025, the compensation committee of BridgeBio's board of directors approved equity grants to 10 new employees in restricted stock units for an aggregate of 30,782 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on February 16, 2026, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan (the “Plan”).
Neutral
GlobeNewsWire
1 week ago
BridgeBio Announces CFO Succession
PALO ALTO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D. has been appointed President and Chief Financial Officer (CFO) of the Company. He recently assumed the role of Principal Financial Officer and will continue to lead the Company's FP&A and accounting operations.
Positive
The Motley Fool
3 weeks ago
Prediction: BridgeBio Pharma Will Beat the Market. Here's Why
Explore the exciting world of BridgeBio Pharma (BBIO -5.42%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Neutral
GlobeNewsWire
1 month ago
BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt
PALO ALTO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $500 million aggregate principal amount of 1.75% convertible senior notes due 2031 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with the offering, the Company granted the initial purchasers an option to purchase up to an additional $75 million aggregate principal amount of notes. The sale of the notes is expected to close on February 28, 2025, subject to customary closing conditions.
Neutral
GlobeNewsWire
1 month ago
BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt
- Long term debt management strategy will strengthen the balance sheet without increasing total liabilities - Refinancing term debt facility lowers interest expense, eliminates near-term amortization payments, and significantly extends debt maturity PALO ALTO, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today that it intends to offer, subject to market conditions and other factors, $500 million aggregate principal amount of convertible senior notes due 2031 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).
Positive
Seeking Alpha
1 month ago
BridgeBio: Strong Start For Attruby
Attruby is off to a strong start in the United States, with more than 1,000 unique prescriptions in less than three months since FDA approval. I now see more patients on Attruby by year-end than I anticipated at launch, although the pace could moderate in Q2 following the approval and launch of Alnylam's Amvuttra. The company's pipeline is advancing as well, with three pivotal trials set to report data within the next 12 months.
Negative
Zacks Investment Research
1 month ago
BridgeBio Pharma (BBIO) Reports Q4 Loss, Tops Revenue Estimates
BridgeBio Pharma (BBIO) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $1.09. This compares to loss of $0.96 per share a year ago.
Charts implemented using Lightweight Charts™